Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: DLK has been an investigator for Amgen, Astellas, AstraZeneca, and Eli Lilly; a speaker and consultant for Amgen, Pfizer, and Eli Lilly; and a member of a drug safety advisory board for Merck. HGB has been an investigator for Amgen, Merck, and Shire; a consultant for Amgen, Merck, Radius Health, and Shire; a speaker for Amgen, Radius Health, and Shire; and a member of a data/safety monitoring board for Grünenthal. FM has no disclosures. EG has been a speaker for Amgen and Takeda, and an advisory board member for UCB and Alexion. SP has been an investigator for Pfizer, Amgen, Gedeon Richter, and Exeltis; a speaker for Bayer Schering, Novo Nordisk, Servier, Pfizer, MSD, Gedeon Richter, ProCare Health, Shionogi, and Teva; and an advisory board member for Novo Nordisk, Gedeon Richter, ProCare Health, and Shionogi. JM and RVD are employees of and hold stock in Amgen. CY was an employee of Amgen at the time of the study and may hold stock in Amgen, and is currently an employee of Cambridge Statistics Ltd. and holds stock in Cambridge Statistics Ltd. SY was an employee of Amgen at the time of the study and may hold stock in Amgen, and is currently an employee of Atara Biotherapeutics and holds stock in Atara Biotherapeutics. CL is an employee of and holds stock in UCB Pharma. AG was an employee of Amgen at the time of the study and may hold stock in Amgen, and is currently an employee of Corcept Therapeutics and holds stock options in Corcept Therapeutics. 17. Radiol Clin North Am. 1991 Jan;29(1):77-84. Osteoporosis. Gillespy T 3rd(1), Gillespy MP. Author information: (1)Department of Radiology, University of Florida, Gainesville. Osteoporosis, a condition of decreased bone tissue that increases the likelihood of fracture, places a significant burden on our society in terms of health cost and morbidity. The most common type of osteoporosis is involutional, and two subtypes are recognized: type 1 and type 2. Type 1, or postmenopausal, osteoporosis is most commonly seen in perimenopausal and postmenopausal women from ages 51 to 75. Estrogen deficiency is the most dominant factor in the pathogenesis of this disorder. Type 2, or aging related, osteoporosis is seen in elderly women and men aged 70 or more. Bone loss in this group is related to aging, estrogen deficiency, negative calcium balance, and a variety of environmental and genetic factors. The best approach to the management of osteoporosis is to develop a lifelong strategy that maximizes peak bone mass and minimizes aging-related and postmenopausal bone loss. Estrogen is the only medication approved for the prevention of bone loss that is in general use. Other strategies to prevent bone loss (and maximize peak bone mass) include adequate calcium intake, adequate exercise, and avoidance of excess alcohol, tobacco, and caffeine use.